Altimmune has been granted a patent for an aqueous acidic formulation that can be used in the preparation of a pharmaceutically acceptable fluorocarbon-linked peptide formulation. The formulation includes a fluorocarbon-linked peptide that is at least 20 amino acid residues long, has at least 50% hydrophobic amino acid residues, and an isoelectric point greater than or equal to 7. The patent also covers a sterile, dried mixture of fluorocarbon-linked immunogenic peptides, which includes peptides with 20 to 50 amino acid residues linked to a fluorocarbon, at least 50% hydrophobic amino acid residues, an isoelectric point greater than or equal to 7, and Hepatitis B virus (HBV) T cell epitopes. The mixture is in a solid form. GlobalData’s report on Altimmune gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Altimmune, recombinant viral vaccines was a key innovation area identified from patents. Altimmune's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
Fluorocarbon-linked immunogenic peptides in solid form
A recently granted patent (Publication Number: US11648305B2) describes a sterile, dried mixture of fluorocarbon-linked immunogenic peptides. The dried mixture consists of one or more fluorocarbon-linked immunogenic peptides that are 20 to 50 amino acid residues long and are linked to a fluorocarbon. These peptides have specific characteristics, including at least 50% hydrophobic amino acid residues, an isoelectric point greater than or equal to 7, and one or more Hepatitis B virus (HBV) T cell epitopes. Importantly, the mixture is in a solid form.
The patent further specifies different forms of the solid mixture. It can be lyophilized as an amorphous cake or a powder. Additionally, the solid form can be achieved through various drying methods such as vacuum drying, spray-drying, freeze drying, or fluid bed drying. In particular, freeze drying is mentioned as a preferred method.
The dried mixture can be stored in different containers, including vials, ampoules, or syringes. It is worth noting that the mixture may also contain a pharmaceutically acceptable carrier, which can enhance its stability and delivery.
The patent also provides details about the fluorocarbon component of the mixture. The fluorocarbon can have a chain length ranging from 3 to 20 carbon atoms, with optional substitutions of fluorine moieties with halogen moieties (Cl, Br, or I), a methyl group, or a hydrogen. One specific example of a fluorocarbon mentioned in the patent is C8F17(CH2)2.
In summary, this granted patent describes a sterile, dried mixture of fluorocarbon-linked immunogenic peptides that have specific characteristics and are in a solid form. The patent covers different forms of the solid mixture, various drying methods, container options, and the fluorocarbon component. This invention has potential applications in the field of immunology and vaccine development.
To know more about GlobalData’s detailed insights on Altimmune, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
